Laekna, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LAE102 for the treatment of patients with obesity. The board of directors of the Company announced that the Group has obtained the IND approval from the U.S. Food and Drug Administration for LAE102, an internally discovered monoclonal antibody against ActRIIA, for the treatment of patients with obesity indication. The Group targets to bring this precision therapy to obesity patients who are in need of novel treatment options.

About LAE102 LAE102 is a monoclonal antibody against ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and dramatically attenuates lean mass loss induced by GLP1R agonist.

This makes LAE102 a drug candidate for achieving quality weight control through reducing fat while keeping muscle mass. Risk warning lae102 may not ultimately be successfully developed and commercialized. The company's shareholders and potential investors are reminded to exercise caution when dealing in the securities of the company.